Aphton Corporation

New approaches promise to change the face of cancer care. Nearly half of the biotechnology drugs in clinical trials (154 of 324) are being developed for the treatment of cancer, according to the Pharm

December deals with Micromet and CancerVax have accelerated Serono's move into oncology. The firm's strengths in biologics development, marketing, and manufacturing should match up well with the requi

Aventis SA 's oncology franchise is anchored by the blockbuster Taxotere (docetaxel). Sales of the drug reached €667 million in the first half of 2003, comprising more than 8% of Aventis's core ph